FDA Awards Priority Review Voucher to Rare Pediatric Disease Product Sponsor

Summary

The FDA has issued a priority review voucher to Wellstat Therapeutics Corp. for its rare pediatric disease product application, Xuriden, following a review of the product's eligibility under the FD&C Act and FDASIA.